your badges 52W Range $3–$19 1% of range Analyst Rating BUY 19 analysts Price Target $26 +697% upside P/E -0.9 ROE -148.7% Net Profit Margin -10998.7%

EYPT Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range

03
Price $3.25
Market Cap (MRQ) $276M
P/E (TTM) -0.9
EPS (TTM) $-3.75
Revenue (TTM) $3M
ROE (TTM) -148.7%
52W Range $3–$19

EYPT Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view

04
range
bars

Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.

Stock splits 2
Ex-date Split Type
Dec. 9, 2020 1-for-10 Reverse
June 11, 2008 1-for-4 Reverse

About EyePoint, Inc. - Common Stock Company overview from Wikipedia

05 · wikidata

EyePoint Pharmaceuticals Inc. (formerly pSivida Corporation) is a Watertown, Massachusetts company specialising in the application of microelectromechanical systems (MEMS) and nanotechnology to drug delivery.

pSivida obtained porous silicon technology from the British government Defence Evaluation and Research Agency (DERA, now QinetiQ). QinetiQ continues to be a strategic partner.

In June 2004, pSivida acquired full ownership of pSiMedica. In April 2018, pSivida purchased eye products firm Icon Bioscience. Afterwards, it rebranded to its current name of EyepOint Pharmaceuticals, Inc.

Source: Wikipedia, CC BY-SA 4.0 · View on Wikipedia ↗

Wikidata ↗

sectorHealthcare industryPharmaceuticals employees214 countryUS

10-Year Performance Revenue, net income, margins and EPS trends

06
Revenue$31M
2017-06-30 → 2025-12-31
EPS$-3.17
2017-06-30 → 2025-12-31
Free Cash Flow$-243M
2019-12-31 → 2025-12-31
Net margin-10998.7%
2019-12-31 → 2025-12-31
Valuation & Ratios 07–12

Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?

Metric 5Y trend EYPT 5Y avg Peer Median Verdict
P/E (TTM) -0.95Y avg ≈-5.8 ≈-5.8 · ·
P/S (TTM) 99.15Y avg ≈19.7 ≈19.7 56.0 Overvalued
P/B (MRQ) 1.75Y avg ≈2.8 ≈2.8 1.6 Overvalued
Price / FCF (TTM) -1.05Y avg ≈-145.0 ≈-145.0 · ·
Price / Cash Flow (TTM) -1.05Y avg ≈116.8 ≈116.8 · ·
Price / Tangible Book 0.95Y avg ≈2.9 ≈2.9 · ·

Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.

value · ≈ 5Y avg · industry median · verdict relative to median

Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date

14
Avg Surprise -7.8%
Next Report Nov 03, 2026
PeriodReportEPS ActualEPS EstSurprise
June 30, 2026 Aug 4, 2026 $-1.09 $-0.97 -12.3%
March 31, 2026 $-0.99 $-0.82 -20.1%
Dec. 31, 2025 $-0.81 $-0.76 -6.2%
Sept. 30, 2025 $-0.85 $-0.80 -6.2%
June 30, 2025 $-0.85 $-0.81 -4.6%
March 31, 2025 $-0.65 $-0.67 2.8%

Full Fundamentals All metrics by year — income statement, balance sheet, cash flow

15
Income Statement 16
Metric Trend 20252024202320222021202020192018201720162015
Revenue $31M$43M$46M$41M$37M$34M$20M$5M$8M$2M$27M
R&D Expense $221M$133M$65M$50M$28M$17M$15M$19M$15M$14M$12M
SG&A Expense $52M$52M$40M$35M$26M$21M$18M$15M$11M$9M$8M
Operating Expenses $275M$189M$121M$141M$92M$72M$68M$44M$26M$23M$20M
Operating Income $-243M$-146M$-75M$-100M$-55M$-37M$-48M$-39M$-19M$-22M$6M
Interest Expense ··$1M$3M$5M$7M$6M$2M$0$0·
Interest Income ··········$19.0K
Other Non-op $12M$15M$7M$2M$292.0K$58.0K$1M$420.0K$91.0K$72.0K$22.0K
Pretax Income $-232M$-131M$-71M$-102M$-58M$-45M$-57M·$-18M$-22M$6M
Income Tax $279.0K$90.0K$83.0K·$0$0$0·$0$-155.0K$96.0K
Net Income $-232M$-131M$-71M$-102M$-58M$-45M$-57M$-86M$-18M$-22M$6M
EPS (Basic) $-3.17$-2.32$-1.82$-2.74$-2.03···$-0.52$-0.68$0.22
EPS (Diluted) $-3.17$-2.32$-1.82$-2.74$-2.03···$-0.52$-0.68$0.21
Shares (Basic) 73,25156,29838,90437,317,00028,758,000···35,343,76531,623,47329,378,250
Shares (Diluted) 73,25156,29838,90437,317,00028,758,000···35,343,76531,623,47330,584,140
EBITDA $-241M$-146M$-75M$-100M$-55M·$-48M··$-22M$6M
Balance Sheet 27
Metric Trend 20252024202320222021202020192018201720162015
Cash & Equivalents $102M$100M$281M$96M$179M$45M$22M$45M$17M$15M$19M
Short-term Investments $204M$271M$50M$49M$33M$0$0$0$0$14M$9M
Inventory $2M$2M$4M$3M$4M$5M$2M$279.0K···
Prepaid Expense $20M$9M$9M$10M$4M$3M$6M$1M$591.0K$483.0K$681.0K
Other Current Assets $2M$1M$1M$782.0K$517.0K······
Current Assets $329M$383M$345M$173M$238M$63M$42M$48M$18M$30M$30M
PP&E (Net) $9M$8M$5M$1M$476.0K$630.0K$357.0K$288.0K$313.0K$290.0K$338.0K
PP&E (Gross) $15M$12M$8M$3M$2M$2M$1M$983.0K$799.0K$2M$2M
Accum. Depreciation $6M$4M$3M$2M$1M$1M$839.0K$695.0K$486.0K$2M$2M
Intangibles ···$0$23M$25M$28M$30M$364.0K$1M$2M
Other Non-current Assets $6M$6M$0········
Total Assets $364M$418M$355M$180M$263M$92M$73M$78M$19M$32M$32M
Accounts Payable $10M$12M$7M$6M$7M$5M$4M$3M$1M$1M$744.0K
Accrued Liabilities $24M$18M$18M$16M$14M$8M$7M$4M$4M$4M$3M
Short-term Debt ··$0$10M$0······
Current Liabilities $37M$49M$63M$35M$24M$15M$12M$21M$5M$5M$3M
Capital Leases $21M$22M$5M$6M$2M$2M$3M$0···
Other Non-current Liabilities $87.0K$205.0K$0$600.0K$2M$2M$3M$1M$51.0K··
Total Liabilities $58M$82M$89M$84M$79M$73M$65M$41M$5M$11M$9M
Long-term Debt ···$30M·······
Total Debt ··$0$40M$37M·$47M····
Common Stock $83.0K$68.0K$49.0K$34.0K$34.0K$18.0K$11.0K$95.0K$39.0K$34.0K$29.0K
Retained Earnings $-1.10B$-873M$-742M$-671M$-569M$-511M$-465M$-408M$-311M$-292M$-271M
AOCI $961.0K$1M$864.0K$786.0K$841.0K$841.0K$840.0K$839.0K$833.0K$852.0K$945.0K
Stockholders' Equity $306M$337M$266M$96M$184M$19M$8M$38M$13M$21M$23M
Liabilities + Equity $364M$418M$355M$180M$263M$92M$73M$78M$19M$32M$32M
Shares Outstanding 82,826,41668,266,00549,043,07434,082,93433,905,82618,139,98110,941,65995,372,23639,356,99934,172,91929,412,365
Cash Flow 18
Metric Trend 20252024202320222021202020192018201720162015
D&A $2M$2M$464.0K········
Stock-based Comp $28M$37M$12M$14M$7M$6M$5M·$2M$2M$2M
Deferred Tax $279.0K$90.0K$83.0K········
Amort. of Intangibles ··$0$2M$2M$2M$2M$981.0K$724.0K$756.0K$770.0K
Restructuring ·····$590.0K··$472.0K··
Other Non-cash $-39M··········
Operating Cash Flow $-240M$-126M$2M$-65M$-50M$-14M$-57M·$-20M$-16M$10M
CapEx $3M$4M$3M$2M$156.0K$362.0K$213.0K·$147.0K$113.0K$161.0K
Investing Cash Flow $69M$-219M$-3M$-17M$-33M$-362.0K$-213.0K·$14M$-4M·
Debt Issued ··$0$30M$0·$50M·$0$0·
Net Debt Issued ·$0$-30M$-8M$0·$30M····
Stock Issued $173M$163M$226M$0·$50M$23M·$8M$16M$0
Net Stock Activity $173M$163M$226M···$23M··$16M·
Financing Cash Flow $174M$164M$187M$-690.0K$217M$37M$34M·$9M$17M·
Net Change in Cash $2M$-182M$186M$-83M$134M$23M$-23M·$2M$-4M$4M
Taxes Paid $200.0K$100.0K·········
Free Cash Flow $-243M$-130M$-2M$-67M$-50M·$-57M··$-16M$10M
Levered FCF ··$-3M$-70M$-56M·$-63M····
Profitability 7
Metric Trend 20252024202320222021202020192018201720162015
Operating Margin -776.0%-337.1%-163.1%-240.6%-149.6%·-235.0%··-1344.1%24.2%
Net Margin -739.4%-302.4%-153.8%-247.0%-158.1%·-278.9%··-1330.1%23.9%
Pretax Margin -738.5%-302.2%-153.7%-247.0%-158.1%·-278.9%··-1339.6%24.2%
EBITDA Margin -768.6%-337.1%-163.1%-240.6%-149.6%·-235.0%··-1344.1%24.2%
ROA -59.3%-33.8%-26.4%-46.1%-32.9%·-75.1%··-67.3%23.1%
ROE -84.0%-47.1%-43.6%-87.9%-42.2%·-468.1%··-90.8%24.8%
ROIC -79.6%-43.4%-28.2%-73.2%-25.0%·-86.2%··-103.5%27.1%
Liquidity & Solvency 5
Metric Trend 20252024202320222021202020192018201720162015
Current Ratio 8.97.85.55.010.0·3.6··5.98.9
Quick Ratio 8.37.65.24.28.9·1.9··5.78.5
Debt / Equity ··0.00.40.2·5.7····
LT Debt / Equity ···0.30.2·5.7····
Interest Coverage ··-60.2-31.2-10.1·-7.7····
Efficiency 1
Metric Trend 20252024202320222021202020192018201720162015
Asset Turnover 0.10.10.20.20.2·0.3··0.11.0
Per Share 5
Metric Trend 20252024202320222021202020192018201720162015
Book Value / Share $3.70$4.93$5.43$2.83$5.44·$0.08··$0.61$0.79
Revenue / Share $428.27$768.64$1.18$1.11·····$0.05$0.87
Cash Flow / Share $-3277.91$-2242.10$0.05$-1.74·····$-0.52$0.34
Cash / Share $1.23$1.46$5.74$2.81$5.27·$0.20··$0.45$0.65
EPS (TTM) $-3.17$-2.32$-1.82$-2.74$-2.03$-0.67$-0.67·$-0.52$-0.68$0.21
Growth Rates 3
Metric Trend 20252024202320222021202020192018201720162015
Revenue YoY -27.5%-6.0%11.1%12.1%7.3%······
Revenue CAGR 3Y -8.8%5.4%10.2%········
Revenue CAGR 5Y -1.8%··········
Valuation (TTM) 14
Metric Trend 20252024202320222021202020192018201720162015
Revenue TTM $31M$43M$46M$41M$37M$34M$20M·$8M$2M$27M
Net Income TTM $-232M$-131M$-71M$-102M$-58M$-45M$-57M·$-18M$-22M$6M
Market Cap $1.51B$509M$1.13B$119M$415M·$1.70B··$967M$1.11B
Enterprise Value ··$802M$15M$240M·$1.72B····
P/E -5.8-3.2-12.7-1.3-6.0-9.8-23.1·-32.9-41.6179.5
P/S 48.211.824.62.911.2·83.3··597.041.7
P/B 4.91.54.31.22.3·203.6··46.347.5
P / Tangible Book 4.91.54.31.22.6······
P / Cash Flow -6.3-4.0604.5-1.8-8.3·-29.9··-59.3107.7
P / FCF -6.2-3.9-704.8-1.8-8.3·-29.8··-58.9109.4
EV / EBITDA ··-10.7-0.1-4.3·-36.0····
EV / FCF ··-499.0-0.2-4.8·-30.2····
EV / Revenue ··17.40.46.5·84.5····
Earnings Yield -17.3%-31.1%-7.9%-78.3%-16.6%-10.2%-4.3%·-3.0%-2.4%0.56%

Most recent period on the left · null values shown as ·

Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years

16
Metric 2025-12-312024-12-312023-12-312022-12-312021-12-31
Revenue $31M $43M $46M $41M $37M
Operating Margin % -776.0% -337.1% -163.1% -240.6% -149.6%
Net Income $-232M $-131M $-71M $-102M $-58M
Diluted EPS $-3.17 $-2.32 $-1.82 $-2.74 $-2.03

Institutional owners (13F) 214 filers · $1.5B total · As of Sept. 30, 2026

17

Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.

Holders 214
Value held $1.5B
New positions 29
Exited positions 21
Institutional activity — Q2 2026 vs prior quarter
New positions Exited positions Increased Decreased Net shares change
29 (-33 vs prior Q) 21 (-2 vs prior Q) 66 (-10 vs prior Q) 60 (+22 vs prior Q) +2.4M

Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.

Institution Value Shares % of tracked 13F Type
MONTANOVA CAPITAL, LLC $118,638,163 8,296,375 8.06% Shares
BlackRock, Inc. $106,723,718 7,463,197 7.25% Shares
Cormorant Asset Management, LP $100,100,000 7,000,000 6.80% Shares
VANGUARD GROUP INC $88,100,480 4,822,139 5.99% Shares
FEDERATED HERMES, INC. $81,239,044 5,681,052 5.52% Shares
ADAGE CAPITAL PARTNERS GP, L.L.C. $69,037,426 4,827,792 4.69% Shares
FRANKLIN RESOURCES INC $68,741,215 4,807,078 4.67% Shares
Commodore Capital LP $65,780,000 4,600,000 4.47% Shares
VANGUARD CAPITAL MANAGEMENT LLC $51,912,604 3,630,252 3.53% Shares
JANUS HENDERSON GROUP PLC $46,419,056 3,601,168 3.15% Shares
Paradigm Biocapital Advisors LP $41,332,677 2,890,397 2.81% Shares
STATE STREET CORP $33,712,894 2,357,545 2.29% Shares
GEODE CAPITAL MANAGEMENT, LLC $29,497,382 2,062,390 2.00% Shares
Aberdeen Group plc $28,725,869 2,008,802 1.95% Shares
PERCEPTIVE ADVISORS LLC $28,600,000 2,000,000 1.94% Put option
CITADEL ADVISORS LLC $28,279,823 1,977,610 1.92% Shares
Balyasny Asset Management L.P. $25,916,719 1,812,358 1.76% Shares
Parkman Healthcare Partners LLC $18,420,731 1,288,163 1.25% Shares
EVENTIDE ASSET MANAGEMENT, LLC $17,811,837 1,245,583 1.21% Shares
TWO SIGMA INVESTMENTS, LP $16,890,345 1,181,143 1.15% Shares
Essex Woodlands Management, Inc. $15,513,455 1,084,857 1.05% Shares
ORBIMED ADVISORS LLC $15,288,802 1,069,147 1.04% Shares
5AM Venture Management, LLC $15,015,000 1,050,000 1.02% Shares
Rosalind Advisors, Inc. $14,131,689 988,230 0.96% Shares
VANGUARD PORTFOLIO MANAGEMENT LLC $13,885,500 971,014 0.94% Shares
AMERIPRISE FINANCIAL INC $12,132,298 848,410 0.82% Shares
DIMENSIONAL FUND ADVISORS LP $12,035,896 841,746 0.82% Shares
HSBC HOLDINGS PLC $11,918,407 833,455 0.81% Shares
Candriam S.C.A. $11,254,258 787,769 0.76% Shares
Artia Global Partners LP $10,969,501 767,098 0.75% Shares
Blue Owl Capital Holdings LP $10,905,094 762,594 0.74% Shares
NORTHERN TRUST CORP $10,309,113 720,917 0.70% Shares
Patient Square Capital LP $10,296,000 720,000 0.70% Shares
Principia Wealth Advisory, LLC $9,293,530 649,944 0.63% Shares
CHARLES SCHWAB INVESTMENT MANAGEMENT INC $9,260,866 647,613 0.63% Shares
Sio Capital Management, LLC $8,910,759 623,130 0.61% Shares
VANGUARD FIDUCIARY TRUST CO $7,996,789 559,216 0.54% Shares
SUSQUEHANNA INTERNATIONAL GROUP, LLP $7,899,320 552,400 0.54% Call option
Alyeska Investment Group, L.P. $7,284,463 509,403 0.50% Shares
MILLENNIUM MANAGEMENT LLC $7,151,330 500,093 0.49% Shares
GOLDMAN SACHS GROUP INC $6,650,744 465,087 0.45% Shares
Simplify Asset Management Inc. $5,720,629 400,044 0.39% Shares
Ikarian Capital, LLC $5,296,720 370,400 0.36% Call option
Ikarian Capital, LLC $5,296,720 370,400 0.36% Put option
Ghisallo Capital Management LLC $5,005,000 350,000 0.34% Shares
STEMPOINT CAPITAL LP $4,840,135 338,471 0.33% Shares
MORGAN STANLEY $4,815,240 336,730 0.33% Shares
E Fund Management Co., Ltd. $4,730,068 330,774 0.32% Shares
Jump Financial, LLC $4,586,825 320,757 0.31% Shares
Bleichroeder LP $4,526,165 316,515 0.31% Shares

Show all 214 institutional owners →

Activists & 5%+ owners 5 positions

18

Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.

Filer Filed Stake Status Purpose Filing
EW Healthcare Partners L.P., EW Healthcare Partners-A L.P., Essex Woodlands Fund IX-GP, L.P., Essex Woodlands IX, LLC, Martin P. Sutter, R. Scott Barry, Ronald Eastman, Petri Vainio, Steve Wiggins ×4 filings Dec. 8, 2023 · Initial filing · SEC
Undisclosed reporting person, Undisclosed reporting person, Undisclosed reporting person, Undisclosed reporting person Aug. 30, 2023 · Initial filing · SEC
Ocumension Therapeutics Jan. 22, 2021 · Initial filing · SEC
IRS Identification Nos. of above persons (entities only) Pfizer Inc. ×2 filings May 26, 2017 · Initial filing · SEC
Pfizer Inc. July 17, 2007 · Initial filing · SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

Company insiders 34 insiders · 14 officers · 22 directors

19
Insider Role Last activity Shares owned Buys 12m Sells 12m Net 12m
Jay S. Duker President and CEO July 10, 2026 M 9,594 1 0 $19,725
Paul Ashton President & CEO March 18, 2016 M 450,741 0 0 $0
George Elston Chief Financial Officer Aug. 20, 2026 G 64,953 0 0 $0
David Price CFO June 25, 2019 A · 0 0 $0
Michael Soja VP Finance, CFO & Treasurer Sept. 10, 2008 A · 0 0 $0
Ramiro Ribeiro Chief Medical Officer June 30, 2026 M 0 0 7 $-948,955
Dario A. Paggiarino Chief Medical Officer March 30, 2024 M 67,080 0 0 $0
David Scott Jones SVP & Chief Commercial Officer Feb. 9, 2024 M 44,916 0 0 $0
Michael Craig Pine Chief Corp Dev.&Strat. Officer Jan. 6, 2024 M 13,662 0 0 $0
Leonard S Ross VP Finance and Chief Accounting Officer June 27, 2019 M 90,044 0 0 $0
Leonard M Blum Executive VP and General Manager, US May 14, 2018 A · 0 0 $0
Debora Jorn EVP, Corp. & Comm'l Dev. June 27, 2017 A · 0 0 $0
Lori Freedman VP Corporate Affairs, General Counsel and Secretary July 21, 2016 A 96,423 0 0 $0
Aaron Finlay Secretary Oct. 18, 2007 A · 0 0 $0
Karen L. Zaderej Director Aug. 18, 2026 P 49,100 1 0 $52,258
Nancy Lurker Director Jan. 6, 2026 M 294,346 0 3 $-150,988
Reginald J. Sanders Director Jan. 2, 2026 A · 0 0 $0
Stuart Duty Director Jan. 2, 2026 A · 0 0 $0
John B. Landis Director Jan. 2, 2026 A 21,400 0 0 $0
Wendy F Dicicco Director Jan. 2, 2026 A 9,967 0 0 $0
ANDO GORAN Director Jan. 2, 2026 A 13,150 0 0 $0
Fred Hassan Director Jan. 2, 2026 A · 0 0 $0
David R Guyer Director July 12, 2024 M 1,850 0 0 $0
Anthony P Adamis Director June 23, 2024 M 4,000 0 0 $0
Ye Liu Director Jan. 11, 2024 S 100,221 0 0 $0
OcuMension Therapeutics Director Jan. 11, 2024 S 100,221 0 0 $0
Douglas Evan Godshall Director June 22, 2021 A 8,016 0 0 $0
Kristine Peterson Director Feb. 28, 2020 A 6,667 0 0 $0
David J Mazzo Director Oct. 9, 2019 M 200,083 0 0 $0
Michael W Rogers Director June 25, 2019 A 119,167 0 0 $0
James J Barry Director May 7, 2018 M 12,500 0 0 $0
SAVAS PETER G Director Dec. 3, 2015 A · 0 0 $0
Paul Hopper Director Dec. 18, 2013 A 10,000 0 0 $0
Katherine Woodthorpe Director Nov. 27, 2007 A · 0 0 $0

Insiders from SEC Form 3/4/5 filings; net = open-market P/S only

ETF ownership Held by 30 ETFs

20

Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.

Fund Weight Units As of Source
PILL · Direxion Shares ETF Trust 1.13% 19,051 NS July 31, 2026 N-PORT
BBC · ETFis Series Trust I 0.63% 23,853 NS July 31, 2026 N-PORT
QQQS · Invesco Exchange-Traded Fund Trust … 0.38% 26,636 SH Oct. 2, 2026 Daily
IWC · iShares Trust 0.08% 263,363 SH Sept. 11, 2026 Daily
IHE · iShares Trust 0.08% 290,098 SH Sept. 11, 2026 Daily
VFMO · VANGUARD WELLINGTON FUND 0.06% 86,797 SH Aug. 19, 2026 Daily
VTWG · VANGUARD SCOTTSDALE FUNDS 0.05% 69,310 SH Aug. 19, 2026 Daily
RSSL · Global X Funds 0.03% 36,951 NS July 31, 2026 N-PORT
VTWO · VANGUARD SCOTTSDALE FUNDS 0.03% 445,218 SH Aug. 19, 2026 Daily
IBBQ · Invesco Exchange-Traded Fund Trust … 0.02% 5,967 SH Oct. 2, 2026 Daily
IWO · iShares Trust 0.02% 607,108 SH Sept. 11, 2026 Daily
DFAS · Dimensional ETF Trust 0.02% 207,955 NS July 31, 2026 N-PORT
FHLC · FIDELITY COVINGTON TRUST 0.01% 35,128 NS July 31, 2026 N-PORT
IWM · iShares Trust 0.01% 1,984,162 SH Sept. 11, 2026 Daily
VXF · VANGUARD INDEX FUNDS 0.01% 901,417 SH Aug. 19, 2026 Daily
VTWV · VANGUARD SCOTTSDALE FUNDS 0.01% 11,210 SH Aug. 19, 2026 Daily
VHT · VANGUARD WORLD FUND 0.01% 213,549 SH Aug. 19, 2026 Daily
PRFZ · Invesco Exchange-Traded Fund Trust 0.01% 60,232 SH Oct. 2, 2026 Daily
WSML · iShares Trust 0.00% 4,573 SH Sept. 11, 2026 Daily
DCOR · Dimensional ETF Trust 0.00% 5,922 NS July 31, 2026 N-PORT
DFAC · Dimensional ETF Trust 0.00% 48,608 NS July 31, 2026 N-PORT
DFAU · Dimensional ETF Trust 0.00% 10,667 NS July 31, 2026 N-PORT
DFUS · Dimensional ETF Trust 0.00% 16,256 NS July 31, 2026 N-PORT
ITOT · iShares Trust 0.00% 111,657 SH Sept. 11, 2026 Daily
IWV · iShares Trust 0.00% 22,216 SH Sept. 3, 2026 Daily
VTI · VANGUARD INDEX FUNDS 0.00% 2,643,860 SH Aug. 19, 2026 Daily
VTHR · VANGUARD SCOTTSDALE FUNDS 0.00% 6,035 SH Aug. 19, 2026 Daily
IWN · iShares Trust · 121,398 SH Sept. 11, 2026 Daily
ISCB · iShares Trust · 3,155 SH Sept. 11, 2026 Daily
ISCV · iShares Trust · 15,627 SH Sept. 11, 2026 Daily

EYPT Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside

21
rating · 19 analysts BUY
Median target $20.00 +515.4%
6 31.6% Strong Buy
7 36.8% Buy
6 31.6% Hold
0 0.0% Sell
0 0.0% Strong Sell

12-Month Price Target

11 analysts · 2026-09-30

Mean target $25.91 +697.2%

← Below all targets Current price $3.25
Low$4.00 Mean$25.91 High$68.00

Peer comparison (GICS sub-industry) Key metrics vs sector peers

22

FY basis, prices as of each company's last fiscal year-end close.

Ticker Market Cap P/E Rev YoY Net Margin ROE Gross Margin
EYPT $1.51B -5.8 -27.5% -739.4% -84.0% ·
BIOA $495M -5.9 · -896.1% -28.4% ·
FULC $753M -9.6 2752.0% · -26.6% ·
SIGA $438M 19.1 -31.8% 24.6% 11.4% ·
ANTX $31M -1.0 · · -57.7% ·
ORMP $112M 1.9 -50.4% 3202.5% 37.0% 0.65%
LLY · 46.8 44.7% 31.7% 101.2% ·

My Metrics Your personal watchlist — selected rows from Full Fundamentals

26

Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.

Your selection is saved and follows you across all tickers.

Source: SEC 10-Q filed Aug 5, 2026